StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Veklury (remdesivir by Quarter

Veklury (remdesivir — COVID-19 antiviral) — Worldwide YoY growth (%) (%)

QuarterlyAnnual

Gilead Sciences Veklury (remdesivir: -81.0% in Q2 2026, down 37.0 pts from a year earlier. That is the lowest of the 19 quarters on record here.

Latest, Q2 2026
-81.0%
Period ended Jun 30, 2026
Change on a year earlier
-37.0 pts
-44.0% in Q2 2025
History
19 quarters
Since Q4 2021
Sources
19
Documents cited below

Where the Q2 2026 figure comes from

“|| Veklury | 23 | 121 | (81)% | 167 | 423 | (60)%”

Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗

Reported in Form 8-K Total Revenue Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVeklury (remdesivir — COVID-19 antiviral) — Worldwide YoY growth (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-81.0%-37.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026-52.0%-7.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-05-07) ↗
Q4 2025Dec 31, 2025-37.0%+16.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗
Q3 2025Sep 30, 2025-60.0%-69.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 2025-44.0%-28.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-08-07) ↗
Q1 2025Mar 31, 2025-45.0%-42.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 2024-53.0%-25.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗
Q3 2024Sep 30, 20249.0%+40.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-11-06) ↗
Q2 2024Jun 30, 2024-16.0%+27.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-08-08) ↗
Q1 2024Mar 31, 2024-3.0%+60.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 2023-28.0%-2.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 2023-31.0%+21.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2023-11-07) ↗
Q2 2023Jun 30, 2023-43.0%+3.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 2023-63.0%-68.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-26.0%+4.0 ptsForm 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗
Q3 2022Sep 30, 2022-52.0%–Form 8-K (exhibit991earningspressrel.htm, filed 2022-10-27) ↗

Cite this data

StockData. (2026). Gilead Sciences Veklury (remdesivir (%), quarterly Q4 2021–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/veklury-total-yoy

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.